Please use this identifier to cite or link to this item:
https://hdl.handle.net/10356/170549
Title: | Transcranial deep-tissue phototherapy for Alzheimer's disease using low-dose X-ray-activated long-afterglow scintillators | Authors: | Ma, Mengmeng Wang, Jing Jiang, Hao Chen, Qiushui Xiao, Yi Yang, Huanghao Lin, Li |
Keywords: | Engineering::Materials | Issue Date: | 2023 | Source: | Ma, M., Wang, J., Jiang, H., Chen, Q., Xiao, Y., Yang, H. & Lin, L. (2023). Transcranial deep-tissue phototherapy for Alzheimer's disease using low-dose X-ray-activated long-afterglow scintillators. Acta Biomaterialia, 155, 635-643. https://dx.doi.org/10.1016/j.actbio.2022.10.049 | Journal: | Acta Biomaterialia | Abstract: | Non-invasive phototherapy has been emerging as an ambitious tactic for suppression of amyloid-β (Aβ) self-assembly against Alzheimer's disease (AD). However, it remains a daunting challenge to develop efficient photosensitizers for Aβ oxygenation that are activatable in a deep brain tissue through the scalp and skull, while reducing side effects on normal tissues. Here, we report an Aβ targeted, low-dose X-ray-excitable long-afterglow scintillator (ScNPs@RB/Ab) for efficient deep-brain phototherapy. We demonstrate that the as-synthesized ScNPs@RB/Ab is capable of converting X-rays into visible light to activate the photosensitizers of rose bengal (RB) for Aβ oxygenation through the scalp and skull. We show that the ScNPs@RB/Ab persistently emitting visible luminescence can substantially minimize the risk of excessive X-ray exposure dosage. Importantly, peptide KLVFFAED-functionalized ScNPs@RB/Ab shows a blood-brain barrier permeability. In vivo experimental results validated that ScNPs@RB/Ab alleviated Aβ burden and slowed cognitive decline in triple-transgenic AD model mice at extremely low X-ray doses without side effects. Our study paves a new pathway to develop high-efficiency transcranial AD phototherapy. STATEMENT OF SIGNIFICANCE: Non-invasive phototherapy has been emerging as an ambitious tactic for suppression of amyloid-β (Aβ) self-assembly against Alzheimer's disease (AD). However, it remains a daunting challenge to develop efficient photosensitizers for Aβ oxygenation that are activatable in a deep brain tissue through the scalp and skull, while reducing side effects on normal tissues. Herein, we report an Aβ targeted, low-dose X-ray-excitable long-afterglow scintillators (ScNPs@RB/Ab) for efficient deep-brain phototherapy. In vivo experimental results validated that ScNPs@RB/Ab alleviated Aβ burden and slowed cognitive decline in triple-transgenic AD model mice at extremely low X-ray doses without side effects. | URI: | https://hdl.handle.net/10356/170549 | ISSN: | 1742-7061 | DOI: | 10.1016/j.actbio.2022.10.049 | Research Centres: | Institute for Digital Molecular Analytics and Science (IDMxS) | Rights: | © 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. | Fulltext Permission: | none | Fulltext Availability: | No Fulltext |
Appears in Collections: | IDMxS Journal Articles |
SCOPUSTM
Citations
20
10
Updated on Dec 5, 2024
Web of ScienceTM
Citations
50
2
Updated on Oct 27, 2023
Page view(s)
149
Updated on Dec 12, 2024
Google ScholarTM
Check
Altmetric
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.